While conducting the CLEAR SYNERGY (OASIS 9) trial, lead author Sanjit Jolly, MD continued to treat some of his patients post–myocardial infarction (MI), including his late father, with colchicine.

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

Please provide your email address to receive an email when new articles are posted on . For patients with stable coronary artery disease, colchicine conferred lower total plaque volume as measured by ...

The Co-STAR trial tested the performance of colchicine in preventing new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. The choice of periprocedural treatment with colchicine was ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...